{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Lurasidone+40mg", "query": { "intervention": "Lurasidone 40mg" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-16T04:37:20.662Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01911429", "title": "Pediatric Schizophrenia Efficacy and Safety Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "Lurasidone 40 mg", "type": "DRUG" }, { "name": "Lurasidone 80 mg", "type": "DRUG" }, { "name": "Placebo 40 or 80 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sumitomo Pharma America, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "13 Years to 17 Years" }, "enrollment_count": 327, "start_date": "2013-08", "completion_date": "2015-12", "has_results": true, "last_update_posted_date": "2017-04-18", "last_synced_at": "2026-09-16T04:37:20.662Z", "location_count": 36, "location_summary": "Dothan, Alabama • Anaheim, California • Bakersfield, California + 33 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Anaheim", "state": "California" }, { "city": "Bakersfield", "state": "California" }, { "city": "Culver City", "state": "California" }, { "city": "Downey", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01911429" }, { "nct_id": "NCT00615433", "title": "Lurasidone HCl A Phase 3 Study of Patients With Acute Schizophrenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "Lurasidone", "type": "DRUG" }, { "name": "Olanzapine", "type": "DRUG" }, { "name": "Placebo comparator", "type": "DRUG" }, { "name": "Lurasidone 40 mg tablets", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sumitomo Pharma America, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 478, "start_date": "2008-01", "completion_date": "2010-01", "has_results": true, "last_update_posted_date": "2015-06-12", "last_synced_at": "2026-09-16T04:37:20.662Z", "location_count": 25, "location_summary": "Little Rock, Arkansas • Cerritos, California • Oceanside, California + 20 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Cerritos", "state": "California" }, { "city": "Oceanside", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00615433" }, { "nct_id": "NCT00044044", "title": "A Comparison of Study Drug With Placebo and Haloperidol in Patients With Schizophrenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "Lurasidone 20 mg", "type": "DRUG" }, { "name": "Lurasidone 40mg", "type": "DRUG" }, { "name": "Lurasidone 80 mg", "type": "DRUG" }, { "name": "Haloperidol 10mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sumitomo Pharma America, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 356, "start_date": "2002-07", "completion_date": "2003-05", "has_results": true, "last_update_posted_date": "2014-04-17", "last_synced_at": "2026-09-16T04:37:20.662Z", "location_count": 34, "location_summary": "Birmingham, Alabama • Cerritos, California • Garden Grove, California + 26 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Cerritos", "state": "California" }, { "city": "Garden Grove", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "La Mesa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00044044" }, { "nct_id": "NCT01082276", "title": "Rifampin Drug-Drug Interaction Study With Lurasidone HCl", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Male, Healthy Normal Subjects" ], "interventions": [ { "name": "Lurasidone HCl", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sumitomo Pharma America, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "MALE", "summary": "18 Years to 45 Years · Male only" }, "enrollment_count": 20, "start_date": "2008-08", "completion_date": "2008-08", "has_results": false, "last_update_posted_date": "2011-09-08", "last_synced_at": "2026-09-16T04:37:20.662Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01082276" }, { "nct_id": "NCT00088634", "title": "A Study to Test the Effectiveness and Safety of a New Medication in the Treatment of Schizophrenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "Lurasidone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sumitomo Pharma America, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 180, "start_date": "2004-05", "completion_date": "2004-12", "has_results": true, "last_update_posted_date": "2016-04-08", "last_synced_at": "2026-09-16T04:37:20.662Z", "location_count": 22, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Cerritos, California + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Cerritos", "state": "California" }, { "city": "Garden Grove", "state": "California" }, { "city": "La Mesa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00088634" }, { "nct_id": "NCT01082146", "title": "RI-AME Study OF [ISOTHIAZOLYL-3-14C]-LURASIDONE", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pharmacokinetics", "Metabolism" ], "interventions": [ { "name": "Lurasidone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sumitomo Pharma America, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "MALE", "summary": "18 Years to 45 Years · Male only" }, "enrollment_count": 6, "start_date": "2008-08", "completion_date": "2008-08", "has_results": false, "last_update_posted_date": "2014-04-03", "last_synced_at": "2026-09-16T04:37:20.662Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01082146" }, { "nct_id": "NCT00044005", "title": "Safety and Tolerability Study of Drug to Treat Schizophrenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "Lurasidone 20 mg", "type": "DRUG" }, { "name": "Lurasidone 40 mg", "type": "DRUG" }, { "name": "Lurasidone 80mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sumitomo Pharma America, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 98, "start_date": "2002-09", "completion_date": "2003-11", "has_results": true, "last_update_posted_date": "2014-04-17", "last_synced_at": "2026-09-16T04:37:20.662Z", "location_count": 26, "location_summary": "Birmingham, Alabama • Cerritos, California • Garden Grove, California + 21 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Cerritos", "state": "California" }, { "city": "Garden Grove", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "La Mesa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00044005" }, { "nct_id": "NCT00549718", "title": "Lurasidone HCl: A Phase 3 Study of Patients With Acute Schizophrenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "Lurasidone HCl", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sumitomo Pharma America, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 489, "start_date": "2007-10", "completion_date": "2010-10", "has_results": true, "last_update_posted_date": "2014-06-11", "last_synced_at": "2026-09-16T04:37:20.662Z", "location_count": 21, "location_summary": "Little Rock, Arkansas • Cerritos, California • Costa Mesa, California + 18 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Cerritos", "state": "California" }, { "city": "Costa Mesa", "state": "California" }, { "city": "Garden Grove", "state": "California" }, { "city": "Paramount", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00549718" }, { "nct_id": "NCT01731119", "title": "Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Schizophrenia", "Schizoaffective Disorder", "Schizophreniform Disorder", "Psychosis NOS", "Autistic Disorder", "Asperger Syndrome", "Child Development Disorders, Pervasive", "Bipolar I Disorder", "Bipolar II Disorder", "Mood Disorder NOS", "Severe Major Depression With Psychotic Features", "Single Episode Major Depression Without Psychotic Symptoms", "Severe Mood Disorder With Psychotic Features" ], "interventions": [ { "name": "Latuda©", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of North Carolina, Chapel Hill", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "19 Years", "sex": "ALL", "summary": "6 Years to 19 Years" }, "enrollment_count": 9, "start_date": "2012-12", "completion_date": "2014-08", "has_results": true, "last_update_posted_date": "2017-06-14", "last_synced_at": "2026-09-16T04:37:20.662Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01731119" }, { "nct_id": "NCT02199743", "title": "Lurasidone Effects on Tissue Glutamate in Schizophrenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Schizophrenia", "Schizoaffective Disorder" ], "interventions": [ { "name": "Lurasidone", "type": "DRUG" }, { "name": "Haloperidol", "type": "DRUG" }, { "name": "Perphenazine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 35, "start_date": "2013-02", "completion_date": "2016-06", "has_results": true, "last_update_posted_date": "2021-03-01", "last_synced_at": "2026-09-16T04:37:20.662Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02199743" } ] }